CBI's 5th Annual Medical Device and Diagnostic Marketing Compliance Congress
Control Off-Label Promotion Liability Risks and Examine Revised Guidance Impact on Industry
June 15, 2009
Westin Arlington Gateway
Arlington, VA
Health Law & Life Sciences Practice Group Partner Michael Manthei will be speaking at CBI's 5th Annual Medical Device and Diagnostic Marketing Compliance Congress. The conference will focus on actionable strategic risk-management practices and supply attendees with critical enforcement updates. Mr. Manthei's program is titled, "Control Off-Label Promotion Liability Risks and Examine Revised Guidance Impact on Industry." He and a representative of Salient Surgical Technologies will be discussing the following:
- Liability risks associated with off-label promotion
- Establishing company-wide buy-in to minimize off-label risks
- Limitations and best practices for distributing educational information to HCPs
- Examining new guidances from FDA Good Reprint Practices
- Current and expected legal enforcement consequences of off-label promotion.
The event will be held at the Westin Arlington Gateway in Arlington, VA from June 15-16, 2009.